Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prosthetic Fixation in THA
NCT02333344Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Jul 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Prosthetic transverse translation at 24 months. Planned start Jul 2015; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02333344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333344.